Aptorum Group Ltd Class A (APM) Stock
APM is no longer traded. Aptorum Group Ltd Class A was delisted from the Nasdaq in November 2025.
Prices on this page are historical; the last trade was November 20, 2025 at $0.00.
Aptorum Group Ltd Class A stock price history
APM final trading statistics
- Final close
- $0.00
- Final trading day
- Nov 20, 2025
- Market cap at delisting
- $570.1K
- Shares outstanding
- 0.63M
- Final 52-week range
- $0.00 – $0.00
- Avg. volume (final 3 mo.)
- 572,489
- All-time high (split-adj.)
- $0.04 · Jun 2020
- All-time low (split-adj.)
- $0.00 · Mar 2020
- Return since IPO
- +0.0%
- Beta
- 0.17
- Book value / share
- $28.38
- Price / book
- 0.00
Aptorum Group Ltd Class A annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$1.4M | -$3.50 |
| FY2024 | $0.00 | -$4.3M | — |
| FY2023 | $431.4K | -$2.8M | — |
| FY2022 | $1.30M | -$9.8M | — |
| FY2021 | $1.54M | -$25.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Aptorum Group Ltd Class A stock FAQ
What happened to Aptorum Group Ltd Class A stock?
Aptorum Group Ltd Class A stock was delisted from the Nasdaq. Its final close was $0.00 on November 20, 2025.
Is APM stock still trading?
No. APM was delisted from the Nasdaq in November 2025 and no longer trades on a U.S. exchange.
What was the last price of APM stock?
APM closed at $0.00 on its final trading day, November 20, 2025, for a market value of about $570.1K.
What were Aptorum Group Ltd Class A's revenue and earnings in its last full fiscal year?
Aptorum Group Ltd Class A reported revenue of $0.00 and net income of -$1.4M in fiscal 2025, its last full year as a public company.
When did Aptorum Group Ltd Class A go public?
Aptorum Group Ltd Class A stock began trading on December 18, 2018.